Parsons Capital Management Inc. RI Decreases Stake in Eli Lilly and Company $LLY

Parsons Capital Management Inc. RI trimmed its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 9.4% during the second quarter, Holdings Channel reports. The fund owned 23,695 shares of the company’s stock after selling 2,459 shares during the quarter. Eli Lilly and Company accounts for 1.1% of Parsons Capital Management Inc. RI’s investment portfolio, making the stock its 13th largest holding. Parsons Capital Management Inc. RI’s holdings in Eli Lilly and Company were worth $18,471,000 as of its most recent filing with the SEC.

Other institutional investors have also recently added to or reduced their stakes in the company. Brighton Jones LLC increased its holdings in Eli Lilly and Company by 22.0% in the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock valued at $7,409,000 after buying an additional 1,730 shares during the last quarter. Revolve Wealth Partners LLC lifted its holdings in Eli Lilly and Company by 2.8% during the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock worth $1,136,000 after buying an additional 40 shares during the last quarter. ST Germain D J Co. Inc. grew its position in shares of Eli Lilly and Company by 3.4% in the 1st quarter. ST Germain D J Co. Inc. now owns 1,667 shares of the company’s stock worth $1,377,000 after acquiring an additional 55 shares in the last quarter. HBW Advisory Services LLC increased its holdings in shares of Eli Lilly and Company by 1.4% in the 1st quarter. HBW Advisory Services LLC now owns 1,648 shares of the company’s stock valued at $1,361,000 after acquiring an additional 23 shares during the last quarter. Finally, Triangle Securities Wealth Management raised its position in shares of Eli Lilly and Company by 30.3% during the 1st quarter. Triangle Securities Wealth Management now owns 4,814 shares of the company’s stock valued at $3,976,000 after acquiring an additional 1,120 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on LLY. Deutsche Bank Aktiengesellschaft reduced their price target on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating on the stock in a research report on Monday, August 11th. DZ Bank upgraded Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 14th. Daiwa Capital Markets lowered shares of Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 target price for the company. in a research note on Sunday, August 17th. Daiwa America cut Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Sunday, August 17th. Finally, Guggenheim reduced their price objective on Eli Lilly and Company from $942.00 to $875.00 and set a “buy” rating for the company in a research report on Wednesday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $939.61.

Eli Lilly and Company Stock Performance

Shares of NYSE LLY opened at $825.92 on Thursday. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $937.00. The firm has a market cap of $781.70 billion, a P/E ratio of 53.98, a PEG ratio of 1.06 and a beta of 0.47. The stock has a fifty day moving average price of $733.71 and a two-hundred day moving average price of $766.37. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. During the same quarter in the prior year, the firm posted $3.92 earnings per share. The company’s revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, CEO David A. Ricks bought 1,632 shares of the business’s stock in a transaction that occurred on Tuesday, August 12th. The stock was acquired at an average cost of $644.77 per share, with a total value of $1,052,264.64. Following the completion of the purchase, the chief executive officer directly owned 546,601 shares in the company, valued at approximately $352,431,926.77. This trade represents a 0.30% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. Also, Director Jamere Jackson bought 200 shares of Eli Lilly and Company stock in a transaction that occurred on Friday, August 8th. The shares were acquired at an average price of $639.56 per share, with a total value of $127,912.00. Following the completion of the acquisition, the director directly owned 9,402 shares of the company’s stock, valued at $6,013,143.12. This represents a 2.17% increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders have purchased 4,514 shares of company stock worth $2,894,841. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.